BBNX vs CBLL: fair value comparison
Beta Bionics, Inc. and CeriBell, Inc · Updated 2026-10-19
BBNX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CBLL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BBNX currently ranks higher by quality score.
| BBNX | CBLL | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $16.35 | $25.04 |
| 12-month range | $8.86–$31.99 | $10.92–$27.64 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #96 of 301 Healthcare | #97 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: BBNX fair value analysis · CBLL fair value analysis